Monograph
A10BD07 - Metformin and Sitagliptin |
Propably not porphyrinogenic |
PNP |
Rationale
Neither metformin nor sitagliptin have the potential to inhibit or induce CYP enzymes. No porphyrinogenic physiological effects. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition and motivates attendance.
Therapeutic characteristics
Metformin and sitagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition intake.
Metabolism and pharmacokinetics
Metformin: Not a Cyp-substrate. Sitagliptin: Approximately 79 per cent of sitagliptin is excreted unchanged in the urine.
Nonclinical studies indicate that the small portion of sitagliptin that undergoes biotransformation is metabolized by Cyp3A4 with the help of Cyp2C8.
In vitro data has shown that sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2Experiental and clinical data indicate that there is low risk for pharmacokinetic interactions with Cyp-metabolized drugs.
IPNet drug reports
Metformin (ATC code: A10BA02) 30 reports of uneventful use. Sitagliptin: No EPNET drug reports.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
Scheen AJ. Diabetes Obes Metab. 2010 Aug; 12(8):648-58. |
20590741 |
| 2. |
Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.
Tornio A, Niemi M, et al. Trends Pharmacol Sci. 2012 Jun;33(6):312-22. |
22475684 |
| * | Summary of Product Characteristics |
| 3. |
The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Janumet.
|
|
| * | Other sources |
| 4. |
See also the monographs of metformin (ATC A10BA02) and of sitagliptin (ATC A10BH01).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
